{'fraction_non_alphanumeric': 0.022002200220022004, 'fraction_numerical': 0.0, 'mean_word_length': 5.842105263157895, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnical and regulatory aspects

Drug metabolism and related drug interactions represent relevant public health issues. The response to drugs is sometimes unpredictable from one individual to another. Interindividual variability in drug and/or metabolite plasma concentrations may result in adverse drug reactions (ADRs) or ineffective drug response. This variability in drug plasma concentration is frequently due to metabolic drug-drug interactions, sometimes related to ADRs. Therefore, the prevention of potential drug-drug metabolic interactions may be very helpful to increase drug efficacy and decrease ADRs. In light of these facts, Drug Metabolism and Drug Interactions ( DMDI ) is committed to developing the clinical-pharmacological knowledge of drug metabolism and drug interactions, focusing on the following aspects.